Nivolumab monotherapy in metastatic urothelial cancer (mUC): updated efficacy by subgroups and safety results from the CheckMate 032 study
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Nivolumab has shown promising efficacy and acceptable safety in an open-label, multicenter phase...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw373.12 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw373.12 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/784P/2799521 
|
| Verfasserangaben: | J.E. Rosenberg, P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P.A. Ott, F. de Braud, M. Morse, D. Le, D. Jaeger, E. Chan, C. Harbison, C.S. Lin, M. Tschaika, A. Azrilevich, P. Sharma |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 156524740X | ||
| 003 | DE-627 | ||
| 005 | 20220814020810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171110s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw373.12 |2 doi | |
| 035 | |a (DE-627)156524740X | ||
| 035 | |a (DE-576)495247405 | ||
| 035 | |a (DE-599)BSZ495247405 | ||
| 035 | |a (OCoLC)1340981716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rosenberg, Jonathan E. |e VerfasserIn |0 (DE-588)1143996321 |0 (DE-627)1003840612 |0 (DE-576)495247375 |4 aut | |
| 245 | 1 | 0 | |a Nivolumab monotherapy in metastatic urothelial cancer (mUC) |b updated efficacy by subgroups and safety results from the CheckMate 032 study |c J.E. Rosenberg, P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P.A. Ott, F. de Braud, M. Morse, D. Le, D. Jaeger, E. Chan, C. Harbison, C.S. Lin, M. Tschaika, A. Azrilevich, P. Sharma |
| 264 | 1 | |c 11 October 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.11.2017 | ||
| 520 | |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Nivolumab has shown promising efficacy and acceptable safety in an open-label, multicenter phase I/II study in patients (pts) with mUC after ≥1 prior platinum-based therapy (NCT01928394). Here we report updated efficacy and safety results for the overall population based on additional follow-up and outcomes by differing levels of PD-L1 expression.Methods: Pts with mUC, unselected by PD-L1 expression status, received nivolumab 3 mg/kg IV every 2 wk until progression or discontinuation. Pts who met protocol criteria could continue treatment beyond progression and cross over to nivolumab + ipilimumab. Tumor PD-L1 membrane expression was assessed with Dako PD-L1 immunohistochemical staining. Primary endpoint: objective response rate (ORR; RECIST 1.1); other endpoints: safety, progression-free survival (PFS), overall survival (OS), and duration of response.Results: Of 78... | ||
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016,Supplement 6) Artikel-Nummer 784P, 1 Seite |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Nivolumab monotherapy in metastatic urothelial cancer (mUC) updated efficacy by subgroups and safety results from the CheckMate 032 study |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g supplement:Supplement 6 |a Nivolumab monotherapy in metastatic urothelial cancer (mUC) updated efficacy by subgroups and safety results from the CheckMate 032 study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw373.12 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/suppl_6/784P/2799521 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171110 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 11 | ||
| 999 | |a KXP-PPN156524740X |e 2986949614 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 10.11.2017"],"origin":[{"dateIssuedDisp":"11 October 2016","dateIssuedKey":"2016"}],"title":[{"title":"Nivolumab monotherapy in metastatic urothelial cancer (mUC)","subtitle":"updated efficacy by subgroups and safety results from the CheckMate 032 study","title_sort":"Nivolumab monotherapy in metastatic urothelial cancer (mUC)"}],"person":[{"display":"Rosenberg, Jonathan E.","family":"Rosenberg","given":"Jonathan E.","role":"aut"},{"role":"aut","given":"Dirk","family":"Jäger","display":"Jäger, Dirk"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["J.E. Rosenberg, P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P.A. Ott, F. de Braud, M. Morse, D. Le, D. Jaeger, E. Chan, C. Harbison, C.S. Lin, M. Tschaika, A. Azrilevich, P. Sharma"]},"language":["eng"],"recId":"156524740X","relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Nivolumab monotherapy in metastatic urothelial cancer (mUC) updated efficacy by subgroups and safety results from the CheckMate 032 studyAnnals of oncology","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"pubHistory":["1.1990 -"],"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"part":{"year":"2016","volume":"27","text":"27(2016,Supplement 6) Artikel-Nummer 784P, 1 Seite"},"language":["eng"]}],"id":{"doi":["10.1093/annonc/mdw373.12"],"eki":["156524740X"]}} | ||
| SRT | |a ROSENBERGJNIVOLUMABM1120 | ||